Skip to main content
OpenTrials
Completed

NCT Number: NCT04518735

Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study)

CORONA is a retrospective, observational, one center study to investigate the clinical evolution (in terms of survival and thromboembolic complications) of patients on chronic treatment with anticoagulants or antiplatelet agents who are admitted to the hospital for COVID-19 compared with patients who do not receive anticoagulants or antiplatelet agents.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Covid19 COVID-19 Coronaviridae Infections Coronavirus Infections Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Hospital de la Santa Creu i Sant Pau

Barcelona, Catalonia, 08025, Spain

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient admitted for COVID-19 at the Hospital de la Santa Creu i Sant Pau,
  • Positive COVID-19 polymerase chain reaction test
  • Length of stay more than 24 hours

Exclusion criteria

  • No objective diagnose for COVID-19
  • Outpatient
  • Lenght of stay less than 24hours

Treatment and study plan

Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19

Other

Review of medical records during hospitalization and until day 28 post-entry to compare the clinical outcomes depending on previous antithrombotic therapy

Primary outcomes

  1. Mortality

    Time frame: From hospital admission to day 28

  2. Transfer to the Intensive Care Unit (ICU)

    Time frame: From hospital admission to day 28

Secondary outcomes

  1. Thromboembolic complications

    Time frame: From hospital admission to day 28

    Venous thromboembolism, ischemic stroke, myocardial infarction or periferal arterial thrombosis during hospitalization for Covid19

  2. Major bleeding complications

    Time frame: From hospital admission to day 28

    Any bleeding complication grade 3 or 5 according BARC classification

Sponsors and collaborators

Lead sponsor

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Other

Registry information

Official study title

Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients

Acronym: CORONA

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Aug 19, 2020
Registry last updated
Aug 19, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.